An improvement of body weight, dyslipidemia, glucose metabolism, and eGFR may be induced by a relative inhibition of GLUT9 or other mechanism, such as an increase in urinary UA excretion by dotinurad. The gene discussed is SLC2A9; the disease is metabolic syndrome.